Lectin Treatment Affects Malignant Characteristics of TPC-1 Papillary Thyroid Cancer Cells
Lectin Treatment Affects Malignant Characteristics of TPC-1 Papillary Thyroid Cancer Cells
Objective: Abnormal glycosylation is a universal aspect of cancer cells. The altered glycosylation pattern has been originatedfrom changings in expression of glycosylation enzymes which are up-regulating in reply to some oncoproteins in thebiosynthetic pathway of glycans. In this study, it was aimed to show the presence of terminal α-2,3, α-2,6 sialic acid andα-1,6/α-1,2 fucose motifs in TPC-1 papillary thyroid cancer cells. Also it was aimed to examine the changes in viability andmobility of the cells after exogenously specific lectin treatment.Materials and Methods: In this study, the presence of terminal sugar residues in glycan chains on the cell surface wasdemonstrated using lectin histochemistry and lectin blotting techniques in TPC-1 cells. The changes in the cell viability andproliferation after lectin treatment were assessed using the WST-1 test. The Changes in the cell mobility after lectin treatment,however, were assessed using the wound healing test.Results: α-2,3, α-2,6 sialic acid and α-1,6/α-1,2 fucose motifs were widespread in the surface of TPC-1 cells. MAL-II (Maackiaamurensis Lectin II) treatment increased the cell proliferation and mobility of TPC-1 cells. Although SNA (Sambucus nigraAglutinin) and AAL (Aleuria aurantia Lectin) treatment did not significantly affect the cell proliferation, SNA and AAL treatmentsupported the mobility of TPC-1 cells.Conclusion: Lectin treatment affect cancerous properties differently depending on the cell type. Also lectin treatment cansupport the malignant behaviour of cancer. For this reason, it is necessary to understand the mechanisms of the lectin effecton the cancer cells.
___
- 1. Xing M. Molecular pathogenesis and mechanisms of thyroid
cancer. Nat Rev Cancer 2013; 13(3):184-99.
- 2. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging
molecular therapies of advanced thyroid cancer. Mol Aspects Med
2010; 31(2): 215-26.
- 3. KondoT, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid
follicular-cell neoplasia. Nat Rev Cancer 2006; 6(4): 292-306.
- 4. Xing M. Prognostic utility of BRAF mutation in papillary thyroid
cancer. Mol Cell Endocrinol 2010; 321(1): 86-93.
- 5. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation:
what is it really orchestrating in thyroid cancer? Oncotarget 2010;
1(8): 751-6.
- 6. Janknecht R. On the road to immortality: hTERT upregulation in
cancer cells. FEBS Lett 2004; 564(1-2): 9-13.
- 7. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB,
Harley CB, Shay JW, Lichtsteiner S, Wright WE,. Extension of lifespan
by introduction of telomerase into normal human cells.
Science 1998; 279(5349): 349-52.
- 8. Hrdličková R, Nehyba J, Bose HR. Alternatively spliced telomerase
reverse transcriptase variants lacking telomerase activity stimulate
cell proliferation. Mol Cell Biol 2012; 32(21): 4283-96.
- 9. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, Wang E, Artandi
MK, Oro AE, Artandi SE. Conditional telomerase induction causes
proliferation of hair follicle stem cells. Nature 2005; 436(7053):
1048-52
- 10. Reinders J, Sickmann A. Modificomics: posttranslational
modifications beyond protein phosphorylation and glycosylation.
Biomol Eng 2007; 24(2): 169-77.
- 11. Freeze HH, Chong JX, Bamshad MJ, Ng BG. Solving glycosylation
disorders: fundamental approaches reveal complicated pathways.
Am J Hum Genet 2014; 94(2): 161-75.
- 12. Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic
cell phenotype by sialylated glycans. Cancer Metastasis Rev 2012;
31(3-4): 501-18.
- 13. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in
glycosylation as biomarkers for cancer detection. J Clin Pathol
2010; 63(4): 322-9.
- 14. A. Varki, R. Kannagi, and B. P. Toole, “Glycosylation changes in
cancer” in Essentials of Glycobiology, A. Varki, R. D. Cummings, J. D.
Esko et al., Eds., 2009.
- 15. Meany DL, Chan DW. Aberrant glycosylation associated with
enzymes as cancer biomarkers. Clin Proteom 2011; 8(1): 7.
- 16. Martin LT, Marth JD, Varki A, Varki NM. Genetically altered mice
with different sialyltransferase deficiencies show tissue-specific
alterations in sialylation and sialic acid 9-O-acetylation. J Biol
Chem 2002; 277(36): 32930-8.
- 17. De Mejía, E.G. and Prisecaru, V.I., (2005). Lectins as bioactive plant
proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr
45(6): 425-45.
- 18. Ryder SD, Smith JA, Rhodes JM. Peanut lectin: a mitogen for
normal human colonic epithelium and human HT29 colorectal
cancer cells. J Natl Med Assoc 1992; 84(18): 1410-6.
- 19. Singh R, Subramanian S, Rhodes JM, Campbell BJ. Peanut lectin
stimulates proliferation of colon cancer cells by interaction with
glycosylated CD44v6 isoforms and consequential activation of
c-Met and MAPK: functional implications for disease-associated
glycosylation changes. Glycobiology 2006; 16(7): 594-601.
- 20. Mehta S, Chhetra R, Srinivasan R, Sharma SC, Behera D. Ghosh S.
Potential importance of Maackia amurensis agglutinin in nonsmall
cell lung cancer. Biol Chem 2013; 394(7): 889-900.
- 21. Chen J, Liu B, Ji N, Zhou J, Bian HJ, Li CY, Chen F, Bao JK, A novel
sialic acid-specific lectin from Phaseolus coccineus seeds with
potent antineoplastic and antifungal activities. Phytomedicine
2009; 16(4): 352-60.
- 22. Liu Z, Liu B, Zhang ZT, Zhou TT, Bian HJ, Min MW, Liu YH, Chen J,
Bao JK. A mannose-binding lectin from Sophora flavescens induces
apoptosis in HeLa cells. Phytomedicine 2008; 15(10): 867-75.
- 23. Hagiwara K, Collet-Cassart D, Kunihiko K, Vaerman JP. Jacalin:
isolation, characterization, and influence of various factors on its
interaction with human IgA1, as assessed by precipitation and
latex agglutination. Mol Immunol 1988; 25(1): 69-83.
- 24. Ahmed H, Chatterjee BP. Further characterization and
immunochemical studies on the carbohydrate specificity of
jackfruit (Artocarpus integrifolia) lectin. J Biol Chem 1989; 264(16):
9365-72.
- 25. Yu LG, Milton JD, Fernig DG, Rhodes JM. Opposite effects on
human colon cancer cell proliferation of two dietary Thomsen‐
Friedenreich antigen‐binding lectins. J Cell Physiol 2001; 186(2):
282-7.
- 26. Wang Q, Yu LG, Campbell BJ, Milton JD, Rhodes JM. Identification
of intact peanut lectin in peripheral venous blood. Lancet 1998;
352(9143): 1831-2.
- 27. Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D,
Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef
E. Antibody and lectin target podoplanin to inhibit oral squamous
carcinoma cell migration and viability by distinct mechanisms.
Oncotarget 2015; 6(11): 9045-60.
- 28. Kolasińska E, Przybyło M, Janik M, Lityńska A. Towards
understanding the role of sialylation in melanoma progression.
Acta Biochim Pol 2016; 63(3): 533-41.
- 29. Kaptan E, Sancar‐Bas S, Sancakli A, Bektas S, Bolkent S. The effect
of plant lectins on the survival and malignant behaviors of thyroid
cancer cells. J Cell Biochem 2018; 119(7): 6274-87.